CME Snack

Novel Approaches to Treating CMV Infection in People Receiving Solid Organ or Hematopoietic Stem Cell Transplantations

Launch Date
05/11/2022
Credit Amount
0.75 Hours
Credit Expires
05/11/2023

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Chief, Infection Control Officer
Director, Clinical Virology Research
Department of Infectious Diseases, Infection Control, and Employee Health The University of Texas MD Anderson Cancer Center Houston, TX
Roy F. Chemaly, MD, MPH, FIDSA, FACP

Roy Chemaly, MD, MPH, CMQ, is the Chief Infection Control Officer and Director of the Clinical Virology Research program. Dr. Chemaly?s interests include studies on epidemiology, severity, prognosis, prevention, and treatment of respiratory viral infections in immunocompromised cancer patients as well as the prevention of health care associated infections. Dr. Chemaly conducts clinical trials for the management and prevention of viral infections in cancer patients, Hematopoietic Cell Transplant (HCT) recipients, as well as on the composition of the upper respiratory tract microbiome as a risk factor for lower respiratory tract infections. He is also conducting clinical trials using CMV specific immuno-assays to predict CMV reactivation or progression. In addition, Dr. Chemaly and his lab team are conducting studies on whole genome sequencing for vancomycin-resistant enterococci (VRE), phages, and CMV to establish the transmission networks and the resistance and virulence genes associated with worse outcomes, respectively. His work in viral infections in HCT recipients has led to landmark publications in high impact journals like New England Journal of Medicine, Annals of Internal Medicine, Blood, and Clinical Infectious Diseases. He is the founder and past chair of the Transplant Infectious Diseases Special Interest Group of the American Society of Bone Marrow Transplantation (ASBMT) and is a member of the writing committee of the ASBMT guidelines for transplant infectious diseases, and the European Committee for Infections in Leukemia (ECIL 8). He is the co-chair of the Infection & Immune Reconstitution Working Committee of the American Society for Transplantation and Cellular Therapy (ASTCT)/Center for International Blood Marrow Transplant Research (CIBMTR), an executive member on the council for the International Immunocompromised Host Society (ICHS), and the scientific officer for the working group on respiratory viruses (ESGREV) of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID).

Genovefa Papanicolaou, MD, FIDSA
Attending Physician, Infectious Disease Service
Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical, Cornell University New York, NY
Genovefa Papanicolaou, MD, FIDSA

Dr. Genovefa Papanicolaou is the Director of Clinical Trials of the Infectious Disease Service at Memorial Sloan Kettering Cancer Center and Professor at Weill Cornell Medical College of Cornell University. Dr. Papanicolaou is the current Chair of the Infectious Disease Special Interest Group (ID-SIG) of the American Society for Transplantation and Cellular Therapy (ASTCT). Her research focuses in viral infections after stem cell transplantation and particularly cytomegalovirus (CMV). Her areas of interest are novel therapeutics, biomarkers, and personalized infection management.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

Cytomegalovirus (CMV) disease causes significant morbidity and mortality in patients receiving solid organ or hematopoietic stem cell transplants (SOT and HSCT, respectively). If left uncontrolled, CMV can result in high viral loads and end organ damage (EOD) in immunocompromised people. Active CMV infections are associated with additional potentially life-threatening complications, such as venous thrombosis, pneumonitis, and colitis.

It is imperative that clinicians are aware of recently approved treatment options for CMV disease. Additionally, clinicians must also be able to individualize CMV treatment to each patient as well as differentiate the benefits of monotherapy versus combination therapy.

In this CMEO Snack, join expert faculty as they discuss best strategies to identify risk factors of CMV infection, recognize the impact of CMV on treatment outcomes, and ultimately develop balanced treatment plans for patients with CMV disease.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Identify factors that increase the risk of CMV infection.
  • Recognize the impact of CMV infection on treatment outcomes for transplant recipients.
  • Develop balanced treatment plans for patients with CMV disease.

Financial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in transplants, infectious disease, internal medicine, and/or primary care

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

PAs (AAPA) 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until the expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

it is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Chemaly reports the following financial relationships: Advisory Board: ADMA Biologics, Inc.; Janssen Pharmaceuticals, Inc.; Karius, Inc.; Partner Therapeutics, Inc.; Pulmotect, Inc.; and Shionogi Inc. Consultant: Adagio Therapeutics, Inc.; Ansun Biopharma; Genentech, Inc.; Merck & Co., Inc.; Oxford Immunotec USA, Inc.; Qiagen; and Takeda Pharmaceuticals U.S.A., Inc./Shire Pharmaceuticals. Grants: National Institutes of Health (NIH)/National Cancer Institute (NCI) (RO1). Research Support: AiCuris Anti-infective Cures AG; Ansun Biopharma; Chimerix; Eurofins Viracor; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Karius, Inc.; Merck & Co., Inc.; Oxford Immunotec USA, Inc.; and Takeda Pharmaceuticals U.S.A., Inc./Shire Pharmaceuticals

Dr. Papanicolaou reports the following financial relationships: Advisory Board: Cidara Therapeutics, Inc.; CSL Behring; Merck & Co., Inc.; and Takeda Pharmaceuticals U.S.A., Inc. Consultant: AlloVir; Amplyx Pharmaceuticals, Inc.; Octapharma USA, Inc.; and Symbio Grants: Merck & Co., Inc. Research Support: Merck & Co., Inc. and Takeda Pharmaceuticals U.S.A., Inc.

Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)

Janan Sarwar, PharmD (planning committee)

David Modrak, PhD (planning committee)

Evan Luberger (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sharon Tordoff (planning committee)

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

SN-167-051122-20

Novel Approaches to Treating CMV Infection in People Receiving Solid Organ or Hematopoietic Stem Cell Transplantations
Event Date: 05/11/2022